FREQUENTLY ASKED QUESTIONS

Q: What is the collaboration between Vanderbilt University and Deerfield Management Company?

A: Vanderbilt is collaborating with Deerfield, an investment firm dedicated to advancing healthcare, to accelerate the translation of research in Vanderbilt faculty laboratories into clinical therapeutics. Ancora Innovation is a Deerfield company that will support Vanderbilt’s innovative translational research and leverage Deerfield’s expertise in accelerating state-of-the-art drug development. Ancora will fund projects with the aim of discovering novel therapeutics to cure life-altering diseases. Through Ancora, Deerfield has committed up to $65 million in initial funding to support promising Vanderbilt translational research. This collaboration will provide operational support and may make additional capital investments into spin-off companies that emerge from Ancora projects that show commercial potential.

Q: Who is eligible to apply?

A: Principal Investigators whose principal employer is Vanderbilt University or Vanderbilt University Medical Center or who have a faculty appointment at Vanderbilt University or Vanderbilt Medical Center and are therefore subject to Vanderbilt’s institutional policies are eligible to apply.

Q: How can I apply?

A: To submit an application, please register below to create an Ancora Innovation profile. Details will follow.

Q: Does Ancora have a therapeutic area of interest?

A: No – We welcome applications from all therapeutic areas.

Q: How many calls for proposal are there in a year?

A: There will be at least one call for proposals per calendar year.